AFFINITY AND TRANSCRIPTASE TECHNOLOGIES

亲和力和转录酶技术

• 批准号: 6314965
• 负责人: Frederick S Hagen
• 金额: $ 17.24万
• 依托单位: ICOGENEX CORPORATION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6314965
• 关键词: RNA directed DNA polymerase; complementary DNA; enzyme activity; gel electrophoresis; genetic library; method development; neoplasm /cancer genetics; polymerase chain reaction; posttranscriptional RNA processing; translation factor

DESCRIPTION: (Applicant's Description) One out of every three Americans will be afflicted with cancer in their life time. It is a devastating frightening disease which frequently ends in death after much suffering. Progress has been made in the treatment and cures of cancer but the progress has been incremental. Much time, effort, and expense has gone into research to understand and develop a cure for cancer but because of the complexity and resiliency of the disease, no "magic bullet" has been developed. The foregoing research has inspired the National Cancer Institute to develop the goal of obtaining a full set of complete cDNAs from normal, premalignant, and malignant cells to enable the molecular genetic events which predetermine, activate, and maintain malignancies to be determined. Once the differences in transcribed sequences are identified, the structure, activity, and function of the encoded protein(s) will be of prime importance. To provide the greatest utility, the cDNA libraries to be studied should contain complete cDNA clones so that once differences are ascertained, the clones may be directly used for expression and determination of the function of the encoded protein. The present application describes the development of CAP affinity enrichment and enhanced reverse transcriptase technologies which will significantly contribute to the successful establishment of full sets of complete cDNAs of normal and cancerous tissues. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（申请人的描述）每三个美国人中就有一个 在他们的一生中遭受癌症的折磨。这是一种毁灭性的恐惧， 一种经常在痛苦之后死亡的疾病。进展 在治疗和治愈癌症方面取得了进展， 增量。许多时间、精力和费用都投入到研究中， 了解并开发出治疗癌症的方法，但由于癌症的复杂性， 在疾病的恢复力方面，还没有研制出“灵丹妙药”。前述 这项研究启发了国家癌症研究所制定的目标， 从正常的、癌前的和癌旁的组织中获得一整套完整的cDNA， 恶性细胞，使分子遗传事件，预先确定， 激活和维持恶性肿瘤的能力有待确定。一旦出现差异， 转录序列的鉴定，结构，活性和功能， 编码的蛋白质将是最重要的。提供最大的 实用性，待研究的cDNA文库应包含完整的cDNA克隆 因此，一旦确定差异，克隆可以直接用于 表达和确定编码蛋白的功能。的 本申请描述了CAP亲和富集的开发， 增强的逆转录酶技术， 有助于成功建立完整的cDNA集的 正常组织和癌组织。 拟议商业应用：不可用